

found on the Web site <http://www.cdc.gov/od/eaipp/>.

ADDRESSES: The webcast will be broadcast from the Centers for Disease Control and Prevention, 1600 Clifton Road NE., Atlanta, Georgia 30329.

FOR FURTHER INFORMATION CONTACT: Von McClee, Division of Select Agents and Toxins, Office of Public Health Preparedness and Response, Centers for Disease Control and Prevention, 1600 Clifton Road NE., MS A-46, Atlanta, GA 30333; phone: 404-718-2000; email: lsrat@cdc.gov.

SUPPLEMENTARY INFORMATION: This webcast is an opportunity for the affected community (i.e., academic institutions and biomedical centers; commercial manufacturing facilities; federal, state, and local laboratories, including clinical and diagnostic laboratories; research facilities; exhibition facilities; and educational facilities) and other interested individuals to obtain specific guidance and information regarding the import permit program. The webcast will also provide assistance to those interested in applying for an import permit.

Representatives from the Department of Transportation, U.S. Department of Agriculture/Animal and Plant Health Inspection Service, and HHS/CDC will be present during the webcast to address questions and concerns from the web participants.

Individuals who want to participate in the webcast must complete their registration online by October 1, 2014. The registration instructions are located on this Web site: <http://www.cdc.gov/od/eaipp/>. This is a 100% webcast; therefore, no accommodations exist for in-person participation.

Dated: August 8, 2014.

Ron A. Otten,

Acting Deputy Associate Director for Science, Centers for Disease Control and Prevention.

[FR Doc. 2014-19114 Filed 8-12-14; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Community Living

Notice of Meeting of the President's Committee for People With Intellectual Disabilities (PCPID)

AGENCY: Administration on Intellectual and Developmental Disabilities (AIDD Administration for Community Living (ACL), Department of Health and Human Services.

ACTION: Notice of meeting.

DATES: Wednesday, September 3, 2014 from 9:30 a.m. to 5:00 p.m.; Thursday, September 4, 2014 from 9:00 a.m. to 5:00 p.m., and Friday, September 5, 2014 from 9:00 a.m. to 4:00 p.m. (EST).

These meetings will be open to the general public.

ADDRESSES: These meetings will be held in the U.S. Department of Health and Human Services/Hubert H. Humphrey Building located at 200 Independence Avenue SW., Conference Room 505A, Washington, DC 20201.

Individuals who would like to participate via conference call may do so by dialing toll-free 888-566-6303, when prompted enter pass code: 45348. Individuals whose full participation in the meeting will require special accommodations (e.g., sign language interpreting services, assistive listening devices, materials in alternative format such as large print or Braille) should notify Dr. MJ Karimi, PCPID Team Lead, via email at MJ.Karimi@acl.hhs.gov, or via telephone at 202-619-3165, no later than Wednesday, August 27, 2014. The PCPID will attempt to accommodate requests made after that date, *but cannot guarantee the ability to grant requests received after this deadline*. All meeting sites are barrier free, consistent with the Americans with Disabilities Act (ADA) and the Federal Advisory Committee Act (FACA).

Agenda: PCPID Appointees will be sworn-in as Members and receive Departmental training for Special Government Employees. The Committee Members will discuss potential topics, themes, and trends for the PCPID Annual Report to the President.

Additional Information: For further information, please contact Dr. MJ Karimi, Team Lead, President's Committee for People with Intellectual Disabilities, 200 Independence Avenue SW., Room 637D, Washington, DC 20201. Telephone: 202-205-3165. Fax: 202-260-3053. Email: MJ.Karimi@acl.hhs.gov.

SUPPLEMENTARY INFORMATION: The PCPID acts in an advisory capacity to the President and the Secretary of Health and Human Services, through the Administration on Intellectual and Developmental Disabilities, on a broad range of topics relating to programs, services and supports for persons with intellectual disabilities. The PCPID Executive Order stipulates that the Committee shall: (1) Provide such advice concerning intellectual disabilities as the President or the Secretary of Health and Human Services may request; and (2) provide advice to the President concerning the following for people with intellectual disabilities:

(A) Expansion of educational opportunities; (B) promotion of homeownership; (C) assurance of workplace integration; (D) improvement of transportation options; (E) expansion of full access to community living; and (F) increasing access to assistive and universally designed technologies.

Dated: August 7, 2014.

Aaron Bishop,

Commissioner, Administration on Intellectual and Developmental Disabilities (AIDD).

[FR Doc. 2014-19164 Filed 8-12-14; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Identification of Non-Invasive Biomarkers of Coordinate Metabolic Reprogramming in Colorectal Tumor

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the following U.S. Patents and Patent Applications to Cary Pharmaceuticals, Inc. ("Cary") located in Great Falls, VA, USA.

Intellectual Property

1. United States Provisional Patent No. 61/755,891, issued January 23, 2013, entitled "Identification of Non-invasive Biomarkers of Coordinate Metabolic Reprogramming Colorectal Tumor";

2. International Patent Application No. PCT/US2014/012758 filed January 23, 2014 entitled "Compositions and Methods for Detecting Neoplasia" [HHS Reference No. E-020-2013/0-PCT-02]

The patent rights in these inventions have been assigned to the government of the United States of America.

The prospective exclusive license territory may be worldwide and the field of use will be limited to the use of Licensed Patent Rights for the commercial development of an FDA approved diagnostic/prognostic kit or a class III diagnostic test for human colorectal adenoma (non-malignant polyp) and carcinoma.

DATES: Only written comments and/or applications for a license which are received by the NIH Office of